All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Vertex Pharmaceuticals Inc.'s approach to cystic fibrosis (CF) – pairing the approved therapy Kalydeco (ivacaftor) as a "potentiator" with another compound, VX-661, as a "corrector" – gained market-pleasing, top-line, Phase II proof that sent the stock on a skyward ride.